{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:24:17Z","timestamp":1791415457148,"version":"4.3.3"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan\u2010genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time\u2010dependent inhibitor of CYP3A4. These results prompted further evaluation in a Phase 1 clinical study in healthy participants who received midazolam (a sensitive CYP3A4 substrate) without and with simultaneous or staggered doses of bemnifosbuvir. A single simultaneous 550 mg bemnifosbuvir dose increased the total plasma exposure of a single 2 mg midazolam dose by 24% via reversible inhibition. Simultaneous coadministration of bemnifosbuvir 550 mg twice daily increased the total plasma exposure to midazolam by 98% as an outcome of reversible\/time\u2010dependent inhibition and induction. Simultaneous coadministration of a single and repeat dose of bemnifosbuvir increased the total plasma exposure to 1\u2010hydroxymidazolam (primary metabolite of midazolam) by 22% and 27%, respectively. Staggered coadministration generally had a lower effect on plasma exposure to both midazolam and 1\u2010hydroxymidazolam. Conversely, midazolam had no significant effect on the pharmacokinetics of bemnifosbuvir. Overall, bemnifosbuvir was a weak clinical inhibitor (geometric mean ratio &lt;2) of CYP3A4.<\/jats:p>","DOI":"10.1002\/jcph.70170","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:04:33Z","timestamp":1777471473000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug\u2010Metabolizing Enzymes"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7662-1616","authenticated-orcid":false,"given":"Xiao\u2010Jian","family":"Zhou","sequence":"first","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Vo","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Morelli","sequence":"additional","affiliation":[{"name":"Altasciences Company  Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Montrond","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan","family":"Lynch","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pietropaolo","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Belanger","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Good","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Horga","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hammond","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc.  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-19"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227104"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02479-20"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2023-0115"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2305137"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1540"},{"key":"e_1_2_10_8_1","unstructured":"MungurO Berliba E BourgeoisS et\u00a0al.A combination of AT\u2010527 a pan\u2010genotypic guanosine nucleotide prodrug and daclatasvir was well\u2010tolerated and effective in HCV\u2010infected subjects; Poster #THU438.Presented at: The International Liver Congress; August 27\u201329 2020;London UK. Accessed December 12 2025.https:\/\/ateapharma.com\/wp\u2010content\/uploads\/2020\/09\/90cmX140cm_Landscape_EASL2020_20200729_final.pdf"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","unstructured":"JucovA HamidS IliescuL et\u00a0al.Efficacy and safety of bemnifosbuvir and ruzasvir after 8 weeks of treatment in patients with chronic hepatitis C virus (HCV) infection; Poster #TOP\u2010251. Presented at: The European Association for the Study of the Liver Congress; May 7\u201310 2025;The Netherlands. Accessed December 12 2025.https:\/\/www.natap.org\/2025\/EASL\/EASL_84.htm","DOI":"10.1016\/S0168-8278(25)02179-8"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4579-x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S283910"},{"issue":"7","key":"e_1_2_10_12_1","first-page":"601","article-title":"Pharmacokinetic drug\u2013drug interaction and their implication in clinical management","volume":"18","author":"Palleria C","year":"2013","journal-title":"J Res Med Sci"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12496"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1434"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1860"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312808"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2019.1648911"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200216666151103121253"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13095"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.016"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.05.011"},{"key":"e_1_2_10_22_1","unstructured":"ZhouXJ MontrondM PietropaoloK BelangerB HorgaA JH.Pharmacokinetics and metabolism of [14C]\u2010bemnifosbuvir in healthy male participants;Poster #549. Presented at the 36th International Conference on Antiviral Research (ICAR) 2023 Conference 13\u201317March Lyon France. Accessed December 5 2025.https:\/\/ir.ateapharma.com\/static\u2010files\/35859e49\u2010bf62\u20104b32\u201080b1\u20101182e58fec92"},{"key":"e_1_2_10_23_1","unstructured":"ZhouXJ SmithB MontrondM et\u00a0al.Bemnifosbuvir and ruzasvir provided as a fixed\u2010dose combination demonstrates high relative bioavailability to their individual formulations and can be dosed with no regard to food; Poster #1398. Presented atthe Liver Meeting\u00ae 2025 American Association for the Study of Liver Diseases (AASLD) November 7\u201311 2025;2025;Washington D.C. Accessed November 27 2025.https:\/\/www.natap.org\/2025\/AASLD\/AASLD_100.htm"},{"key":"e_1_2_10_24_1","unstructured":"ICH Guidelines.Drug interaction studies M12 (final version). Adopted on May 21 2024. Accessed December 12 2025.https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf"},{"key":"e_1_2_10_25_1","unstructured":"FDA.Drug development and drug interactions: table of substrates inhibitors and inducers.2022. Accessed August 2 2025.https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/drug\u2010development\u2010and\u2010drug\u2010interactions\u2010table\u2010substrates\u2010inhibitors\u2010and\u2010inducers"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010099"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112686"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.668"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00830-0"},{"key":"e_1_2_10_30_1","unstructured":"VoA YJ HafeyMJ WH AgrawalN JPS.Low risk of drug\u2013drug interactions for ruzasvir based uponin vitrometabolism and transporter interaction studies; Poster #SAT\u2010412. Presented at: The European Association for the Study of the Liver Congress; June 5\u20138 2024;Milan Italy. Accessed August 2 2025.https:\/\/docs.publicnow.com\/viewDoc?filename=182430%5CEXT%5C3F131EEB3102289AF8A39B4BF3BEB3F791C60B46_B1363B267228B087602A751CBC05DBD0632AC348.PDF"},{"key":"e_1_2_10_31_1","unstructured":"Food and Drug Administration.Clinical drug interaction studies \u2013 cytochrome P450 enzyme and transporter\u2010mediated drug interactions. Guidance for industry. Accessed August 2 2025.https:\/\/collections.nlm.nih.gov\/master\/borndig\/101767654\/download.pdf"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02632-12"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.660"},{"key":"e_1_2_10_34_1","volume-title":"A phase 1, concentration\u2010QTc analysis shows bemnifosbuvir does not alter cardiac repolarization. Poster #PO419. Presented at European Society of Clinical Microbiology and Infectious Diseases","author":"Zhou XJ","year":"2024"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae122"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007302562"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.087270"},{"key":"e_1_2_10_38_1","unstructured":"ICH Guidelines M12 on drug interaction studies Step 2b. Accessed January 21 2026.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/draft\u2010ich\u2010guideline\u2010m12\u2010drug\u2010interaction\u2010studies\u2010step\u20102b_en.pdf"},{"key":"e_1_2_10_39_1","unstructured":"Food and Drug Administration.Clinical drug interaction studies \u2014 cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry. Accessed January 21 2026.https:\/\/downloads.regulations.gov\/FDA\u20102017\u2010D\u20105961\u20100023\/attachment_1.pdf"},{"key":"e_1_2_10_40_1","unstructured":"ICH Guidelines M12 on drug interaction studies Step 4. Accessed January 22 2026.https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009903900508"},{"key":"e_1_2_10_42_1","unstructured":"Gilead.Vosevi [prescribing information]. Accessed December 1 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209195s003lbl.pdf"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","unstructured":"ZhouXJ MarburyT RondonJC et\u00a0al.Pharmacokinetics of bemnifosbuvir in participants with hepatic impairment. Presented at the European Association for the Study of the Liver (EASL) Congress May 7\u201310 2025; Poster #WED\u2010278;Amsterdam The Netherlands. Accessed December 12 2025.https:\/\/www.natap.org\/2025\/EASL\/EASL_85.htm","DOI":"10.33590\/emjhepatol\/SDVC9205"},{"key":"e_1_2_10_44_1","unstructured":"AbbVie.Mavyret [prescribing information]. Accessed December 1 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209394s019 215110s005lbl.pdf"},{"key":"e_1_2_10_45_1","unstructured":"MerckSD.Zepatier [prescribing information]. Accessed December 1 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208261s007lbl.pdf"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:35:54Z","timestamp":1784547354000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/jcph.70170"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70170","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70170"}}